Journal article · 2010 · Open access

Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs

Ben Markman, Rodrigo Dienstmann, Josep M. Tabernero

Oncotarget, 1(7), 530–543 · Published 22 October 2010 · DOI 10.18632/oncotarget.188

Open PDFView at the publisherCite this paper

In brief

“Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs” is a 2010 journal article by Ben Markman and 2 co-authors, published in Oncotarget. OpenAlex counts 390 citations as of 21 November 2026, which puts it in the top 2% of works published in 2010 by citations. It is open access under a CC BY licence: the full text is free to read at Oncotarget.

Citations
390
Most cited in
2024 (39)
Field-weighted impact
10.31
References
87
Authors
3

Abstract

It is well established that the PI3K pathway plays a central role in various cellular processes that can contribute to the malignant phenotype. Accordingly, pharmacological inhibition of key nodes in this signaling cascade has been a focus in developmental therapeutics. To date, agents targeting upstream receptor tyrosine kinases are best studied and have achieved greatest clinical success. Further downstream, despite efficacy in certain tumor types, the rapalogs have been somewhat disappointing in the clinic. Novel inhibitors of PI3K, Akt, and mTORC1 and 2 are now passing through early phase clinical trials. It is hoped that these agents will circumvent some of the shortcomings of the rapalogs and lead to meaningful benefits for cancer patients.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Markman, B., Dienstmann, R., & Tabernero, J. M. (2010). Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs. Oncotarget, 1(7), 530–543. https://doi.org/10.18632/oncotarget.188

MLA 9

Markman, Ben, et al. “Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs.” Oncotarget, vol. 1, no. 7, 2010, pp. 530–543. https://doi.org/10.18632/oncotarget.188.

Chicago

Markman, Ben, Rodrigo Dienstmann, and Josep M. Tabernero. 2010. “Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs.” Oncotarget 1 (7): 530–543. https://doi.org/10.18632/oncotarget.188.

Harvard

Markman, B., Dienstmann, R. and Tabernero, J. M. (2010) ‘Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs’, Oncotarget, 1(7), pp. 530–543. doi:10.18632/oncotarget.188.

IEEE

B. Markman, R. Dienstmann, and J. M. Tabernero, “Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs,” Oncotarget, vol. 1, no. 7, pp. 530–543, 2010, doi: 10.18632/oncotarget.188.

BibTeX

@article{markman2010targeting,
  title     = {{Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs}},
  author    = {Markman, Ben and Dienstmann, Rodrigo and Tabernero, Josep M.},
  journal   = {Oncotarget},
  year      = {2010},
  volume    = {1},
  number    = {7},
  pages     = {530--543},
  doi       = {10.18632/oncotarget.188},
  url       = {https://doi.org/10.18632/oncotarget.188}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20172121
20182323
20191616
20201414
20211414
20221818
20231414
20243939
202577
202699

Its field-weighted citation impact is 10.31: it has been cited 10.31 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer

  • PI3K/AKT/mTOR pathway
  • rapalogs
  • PI3K inhibitors
  • AKT inhibitors
  • mTOR inhibitors
  • mTORC1
  • mTORC2
  • receptor tyrosine kinase inhibitors

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Markman, B., Dienstmann, R., & Tabernero, J. M. (2010). Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs. Oncotarget, 1(7), 530–543. https://doi.org/10.18632/oncotarget.188

How many times has this paper been cited?

390 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Oncotarget: sign in and open the PDF from this page.

Who wrote this paper?

Ben Markman, Rodrigo Dienstmann, Josep M. Tabernero.

What is the DOI of this paper?

10.18632/oncotarget.188, permanently at https://doi.org/10.18632/oncotarget.188. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.